您当前所在的位置:首页 > 产品中心 > 产品信息
PF-3845_分子结构_CAS_1196109-52-0)
点击图片或这里关闭

PF-3845

产品号 S2666 公司名称 Selleck Chemicals
CAS号 1196109-52-0 公司网站 http://www.selleckchem.com
分子式 C24H23F3N4O2 电 话 (877) 796-6397
分子量 456.4602296 传 真 (832) 582-8590
纯 度 电子邮件 sales@selleckchem.com
保 存 -20°C Chembase数据库ID: 73163

产品价格信息

请登录

产品别名

标题
PF-3845
IUPAC标准名
N-(pyridin-3-yl)-4-[(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)methyl]piperidine-1-carboxamide
IUPAC传统名
N-(pyridin-3-yl)-4-[(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)methyl]piperidine-1-carboxamide

产品登记号

CAS号 1196109-52-0

产品性质

成盐信息 Free Base
保存条件 -20°C

产品详细信息

详细说明 (English)
Research Area
Description Cancer
Biological Activity
Description PF-3845 is a potent, selective and irreversible FAAH inhibitor with Ki of 230 nM.
Targets FAAH
IC50 230 nM (Ki) [1]
In Vitro PF-3845 selectively inhibits FAAH by carbamylating FAAH’s serine nucleophile. [1]
In Vivo PF-3845 treated mice (10 mg/kg, i.p.) shows rapid and complete inactivation of FAAH in the brain, as judged by competitive activity-based protein profiling (ABPP) with the serine hydrolase-directed probe fluorophosphonate (FP)-rhodamine. PF-3845 shows a long duration of action up to 24 hour. PF-3845-treated mice also shows dramatic (>10-fold) elevation in brain levels of AEA and other NAEs (N-pamitoyl ethanolamine [PEA] and N-oleoyl ethanolamine [OEA]). FAAH is AEA-degrading enzyme fatty acid amide hydrolase. PF-3845 (1–30 mg/kg, oral administration [p.o.]) causes a dose dependent inhibition of mechanical allodynia with a minimum effective dose (MED) of 3 mg/kg (rats are analyzed at 4 hour post dosing with PF-3845). At higher doses (10 and 30 mg/kg), PF-3845 inhibits pain responses to an equivalent, if not greater,degree than the nonsteroidal anti-inflammatory drug naproxen (10mg/kg, p.o.). [1] PF-3845 (10 mg/kg, i.p.) significantly reverses LPS-induced tactile allodynia, but doesn’t modify paw withdrawal thresholds in the saline-injected paw. [2]
Clinical Trials
Features
Protocol
Kinase Assay [1]
FAAH Assay The GDH-coupled FAAH assay is performed for determination of potencies (Kinact/ Ki values) of irreversible inhibitors. For the development of structure-activity relationship,the FAAH assay is performed in 384-well microplates with a final volume of 50μL. In the 384-well format assay, the overall potency, Kinact/ Ki values, are generally calculated from the slope, Kinact/[ Ki (1 + [S]/ Km)], which is obtained from the kobs versus [I] linear lines under the conditions of [I] <>i as described (from the kobs values fitted to equation 3 in PNAS 2008). In order to obtainKinact and Ki values separately for PF-3845 and URB597, the FAAH assay is performed in the 96-well format with a final volume of 200μL. Due to its more frequent reading capabilities (every 10 and 30 seconds for the 96- and 384-well formats, respectively), the 96- well format allows a measurement of Kobs values at higher concentrations of inhibitors. The Kinact and Ki values are obtained by fitting the kobs versus [I] curves to the equation, Kobs = Kinact [I]/{[I] + Ki (1 + [S]/ Km}. FAAH inactivation rates in the absence of inhibitors are subtracted from all kobs values obtained in the presence of inhibitors. The ratio Kinact/ Ki calculated from the individual Kinact and Ki values obtained separately agrees well with the Kinact/ Ki value obtained from the slope described above.
Animal Study [1]
Animal Models Male C57BL/6 mice
Formulation PF-3845 is dissolved at 1 mg/ml by sonication and vortexing directly into a solution of 18:1:1 v/v/v saline:emulphor:ethanol.
Doses 10 mg/kg or 1-30 mg/kg
Administration Administered via i.p. 1 hour before sacrificed by CO2 or oral administration.
References
[1] Ahn K et al, Chem Biol, 2009,16(4), 411-20.
[2] Booker L, et al, Br J Pharmacol, 2012, 165(8), 2485-2496.